vs
ASP Isotopes Inc.（ASPI）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
ARS Pharmaceuticals, Inc.的季度营收约是ASP Isotopes Inc.的1.7倍（$28.1M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs -67.6%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
ASPI vs SPRY — 直观对比
营收规模更大
SPRY
是对方的1.7倍
$16.7M
营收增速更快
ASPI
高出1363.2%
-67.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $28.1M |
| 净利润 | — | $-41.3M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -147.6% |
| 净利率 | — | -147.1% |
| 营收同比 | 1295.7% | -67.6% |
| 净利润同比 | -586.8% | -182.8% |
| 每股收益（稀释后） | — | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPISPRY
| Q4 25 | $16.7M | $28.1M | ||
| Q3 25 | $4.9M | $32.5M | ||
| Q2 25 | — | $15.7M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $500.0K | ||
| Q1 24 | — | $0 |
净利润ASPISPRY
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $-12.9M | $-51.2M | ||
| Q2 25 | — | $-44.9M | ||
| Q1 25 | — | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | — | $-12.5M | ||
| Q1 24 | — | $-10.3M |
毛利率ASPISPRY
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ASPISPRY
| Q4 25 | — | -147.6% | ||
| Q3 25 | -306.1% | -163.7% | ||
| Q2 25 | — | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% | ||
| Q1 24 | — | — |
净利率ASPISPRY
| Q4 25 | — | -147.1% | ||
| Q3 25 | -263.7% | -157.4% | ||
| Q2 25 | — | -285.6% | ||
| Q1 25 | — | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | — | -925.0% | ||
| Q2 24 | — | -2503.2% | ||
| Q1 24 | — | — |
每股收益（稀释后）ASPISPRY
| Q4 25 | — | $-0.41 | ||
| Q3 25 | $-0.15 | $-0.52 | ||
| Q2 25 | — | $-0.46 | ||
| Q1 25 | — | $-0.35 | ||
| Q4 24 | — | $0.52 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $245.0M |
| 总债务越低越好 | $14.4M | $96.4M |
| 股东权益账面价值 | $204.2M | $114.3M |
| 总资产 | $498.0M | $327.7M |
| 负债/权益比越低杠杆越低 | 0.07× | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资ASPISPRY
| Q4 25 | $333.3M | $245.0M | ||
| Q3 25 | $113.9M | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
总债务ASPISPRY
| Q4 25 | $14.4M | $96.4M | ||
| Q3 25 | $13.9M | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPISPRY
| Q4 25 | $204.2M | $114.3M | ||
| Q3 25 | $74.1M | $147.7M | ||
| Q2 25 | — | $192.3M | ||
| Q1 25 | — | $229.0M | ||
| Q4 24 | — | $256.8M | ||
| Q3 24 | — | $201.0M | ||
| Q2 24 | — | $215.2M | ||
| Q1 24 | — | $223.9M |
总资产ASPISPRY
| Q4 25 | $498.0M | $327.7M | ||
| Q3 25 | $225.9M | $372.8M | ||
| Q2 25 | — | $313.5M | ||
| Q1 25 | — | $327.3M | ||
| Q4 24 | — | $351.2M | ||
| Q3 24 | — | $217.6M | ||
| Q2 24 | — | $222.0M | ||
| Q1 24 | — | $227.6M |
负债/权益比ASPISPRY
| Q4 25 | 0.07× | 0.84× | ||
| Q3 25 | 0.19× | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPISPRY
| Q4 25 | $-37.8M | $-43.5M | ||
| Q3 25 | $-8.9M | $-47.0M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.7M | ||
| Q4 24 | — | $42.0M | ||
| Q3 24 | — | $-14.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.7M |
自由现金流ASPISPRY
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
自由现金流率ASPISPRY
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
资本支出强度ASPISPRY
| Q4 25 | 57.9% | 0.0% | ||
| Q3 25 | 64.4% | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
现金转化率ASPISPRY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
